Applied Materials reported its fourth-quarter results after Thursday's closing bell. Here's a look at the details from the ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025Company ...

The potential market opportunity is vast, with projected sales reaching $2.5 billion in the US, EU5, and Japan by 2037, assuming a 2% market share. Positive outcomes in AtD could also pave the way for ...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, ...